MLK
MLKs (Mixed-Lineage Kinasen) sind eine Gruppe von Kinasen, die mehrere MAPK-Signalwege, einschließlich JNK und p38, aktivieren können, indem sie die vorgelagerten MAP-Kinase-Kinasen (MAP2Ks) phosphorylieren. MLKs sind an zellulären Stressreaktionen, Apoptose und Neuroinflammation beteiligt. Eine Fehlregulation der MLK-Aktivität wird mit neurodegenerativen Erkrankungen und bestimmten Krebsarten in Verbindung gebracht. Bei CymitQuimica bieten wir eine Reihe hochwertiger MLK-Modulatoren zur Unterstützung Ihrer Forschung in den Bereichen Neurobiologie, Stressreaktionen und Signaltransduktion an.
19 Produkte aus dem Bereich "MLK" gefunden
Sortieren nach
Reinheit (%)
0
100
|
0
|
50
|
90
|
95
|
100
GW806742X
CAS:GW806742X inhibits MLKL with Kd 9.3 μM, preventing necroptosis; also targets VEGFR2.Formel:C25H22F3N7O4SReinheit:98.3%Farbe und Form:SolidMolekulargewicht:573.55Anticancer agent 267
Anticanceragent 267 (Compound 5q) serves as an activator of RIPK3 and MLKL. It effectively inhibits the proliferation of several cancer cell lines, with IC50 values of 9.79, 10.77, and 5.94 μM for MDA-MB-231, MDA-MB-486, and MCF-7, respectively. The compound induces cell cycle arrest at the subG1 phase and triggers necroptosis in MDA-MB-231 cells. Additionally, Anticanceragent 267 demonstrates antitumor activity in mouse xenograft models.Formel:C13H11N5O4SFarbe und Form:SolidMolekulargewicht:333.32PROTAC MLKL Degrader-1
PROTAC MLKL Degrader-1 (Compound 36) is a selective PROTAC degrader targeting MLKL, achieving a degradation maximum (D max) over 90%.Formel:C46H55F2N9O9SFarbe und Form:SolidMolekulargewicht:948.05MLKL-IN-2
CAS:MLKL-IN-2 is an MLKL inhibitor with potential tumorigenic activity for the study of cellular necrosis-related diseases.
Formel:C26H25N5OReinheit:98.30%Farbe und Form:SolidMolekulargewicht:423.51MLKL-IN-7
MLKL-IN-7 (compound 9) is an MLKL inhibitor that exhibits anti-necrotic activity in HT-29 cells, with an IC50 value of 148.4 nM.Formel:C21H15N5O5S2Molekulargewicht:481.05146NecroX-2
CAS:NecroX-2 is a cell-permeable necrosis inhibitor with antioxidant properties. NecroX-2 selectively suppresses necrotic cell death triggered by oxidative stress. NecroX-2 does not confer protection against apoptosis induced by staurosporine or etoposide but shows protective effects under conditions such as cold shock, hypoxia, and oxidative stress in vitro.Formel:C25H32N4O4S2Reinheit:97.12%Farbe und Form:SolidMolekulargewicht:516.68RIPK3-IN-3
RIPK3-IN-3 (compound 20) is a selective RIPK3 inhibitor that demonstrates potent activity with an IC50 value of 10 nM.Formel:C16H11N5SFarbe und Form:SolidMolekulargewicht:305.36PROTAC MLKL Degrader-2
PROTAC MLKL Degrader-2, a PROTAC that targets MLKL (Mixed Lineage Kinase), incorporates the PROTAC target protein ligand, E3 ligase ligand Thalidomide, and PROTAC Linker N-Methylpiperazine. The conjugate of the E3 ubiquitin ligase ligand and Linker is Thalidomide-N-Methylpiperazine. This compound exhibits antinecroptotic activity in human cell lines and effectively degrades MLKL in the HT-29 xenograft mouse model.Formel:C36H35N9O9SFarbe und Form:SolidMolekulargewicht:769.78CEP1347-VHL-02
CEP1347-VHL-02 is a PROTAC that selectively targets MLK3. This compound is composed of the target protein ligand CEP-1347, the E3 ubiquitin ligase ligand (S,R,S)-AHPC-Me, and the PROTAC linker Amino-PEG3-CH2COOH. The participating component responsible for controlling the target protein ligand activity is CEP-1347-acid, whereas the conjugate of the E3 ubiquitin ligase ligand and linker is identified as (S,R,S)-AHPC-Me-CO-CH2-PEG3-NH2.Formel:C61H72N8O11S3Farbe und Form:SolidMolekulargewicht:1189.47MLK-IN-1
CAS:MLK-IN-1 is a potent and selective mixed-lineage kinase 3 (MLK-3) inhibitor, showing excellent brain penetration and high specificity for MLK-3. MLK-IN-1 at 100 nM supports sustained axonogenesis in cultures challenged with HIV-1 Tat-activated microglia and protects neuronal cells from Tat-induced damage, establishing it as a valuable probe for neuroinflammation and neurodegeneration research.Formel:C23H20N4O3SReinheit:99.74%Farbe und Form:SolidMolekulargewicht:432.5Ref: TM-T39102
1mg54,00€5mg114,00€10mg178,00€25mg394,00€50mg620,00€100mg982,00€1mL*10mM (DMSO)126,00€Necrosulfonamide
CAS:Necrosulfonamide ((E)-Necrosulfonamide) is a necroptosis inhibitor that targets MLKL and is selective. High-Quality, Low-Cost!Formel:C18H15N5O6S2Reinheit:98.85% - 99.49%Farbe und Form:SolidMolekulargewicht:461.47MLKL-IN-5
CAS:MLKL-IN-5 is a potent MLKL inhibitor that mediates necroptosis .Formel:C18H20N6O4SFarbe und Form:SolidMolekulargewicht:416.45SZM-1209
CAS:SZM-1209 is a potent and specific RIPK1 inhibitor with oral activity, displaying a dissociation constant (Kd) of 85 nM.Formel:C31H29F5N4O5S2Reinheit:98%Farbe und Form:SolidMolekulargewicht:696.71IM-54
CAS:IM-54 is a cell-permeable, effective, and selective necrosis inhibitor.Formel:C19H23N3O2Reinheit:99.24%Farbe und Form:SolidMolekulargewicht:325.4Ref: TM-T24160
1mg49,00€5mg104,00€10mg164,00€25mg281,00€50mg404,00€100mg567,00€1mL*10mM (DMSO)115,00€TC13172
CAS:TC13172 is a potent, covalent MLKL inhibitor, selective over RIPK1/RIPK3. It blocks TSZ-induced necroptosis (EC50=2nM) and MLKL oligomerization at 100nM.Formel:C17H16N4O5SReinheit:98%Farbe und Form:SolidMolekulargewicht:388.4MLKL-IN-1
MLKL-IN-1 is a covalent inhibitor of MLKL with a Kd value of 50 μM.Formel:C19H20N2O3Farbe und Form:SolidMolekulargewicht:324.37MLKL-IN-6
MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor that specifically targets the Mixed Lineage Kinase domain-like (MLKL) protein.
Formel:C20H18N4O5Reinheit:98%Farbe und Form:SolidMolekulargewicht:394.38Topoisomerase I/II inhibitor 8
CAS:TopoisomeraseI/II inhibitor 8 (Compound Ru7) is a dual catalytic inhibitor of TopoisomeraseI/II that induces DNA damage and activates PARP-1, leading to the activation of RIPK1, RIPK3, and MLKL, ultimately causing necroptosis. It shows significant anticancer activity by effectively targeting cancer cell nuclei and inducing cell death through necroptosis, offering substantial clinical potential in overcoming resistance in cancer treatment.Formel:C14H11Br2NO5S2Farbe und Form:SolidMolekulargewicht:497.179MBA-m1
CAS:MBA-m1 is an MLKL inhibitor that suppresses necroptosis in Mlkl−/−NIH-3T3 cells. Additionally, MBA-m1 alleviates disease conditions in mouse models of dermatitis and abdominal aortic aneurysm induced by MLKL.Formel:C27H21ClN2O2Farbe und Form:SolidMolekulargewicht:440.92
